WO2019117660A3 - Crispr 시스템 기능 향상 방법 및 그의 이용 - Google Patents

Crispr 시스템 기능 향상 방법 및 그의 이용 Download PDF

Info

Publication number
WO2019117660A3
WO2019117660A3 PCT/KR2018/015897 KR2018015897W WO2019117660A3 WO 2019117660 A3 WO2019117660 A3 WO 2019117660A3 KR 2018015897 W KR2018015897 W KR 2018015897W WO 2019117660 A3 WO2019117660 A3 WO 2019117660A3
Authority
WO
WIPO (PCT)
Prior art keywords
sgrna
crispr system
same
compositions
development
Prior art date
Application number
PCT/KR2018/015897
Other languages
English (en)
French (fr)
Other versions
WO2019117660A2 (ko
Inventor
이성욱
이창호
한승렬
김지현
Original Assignee
단국대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 단국대학교 산학협력단 filed Critical 단국대학교 산학협력단
Publication of WO2019117660A2 publication Critical patent/WO2019117660A2/ko
Publication of WO2019117660A3 publication Critical patent/WO2019117660A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

본 발명은 특이적 sgRNA를 이용하여 CRISPR 시스템 기능을 향상시키는방법, 상기 특이적 sgRNA 및 Cas9 폴리펩타이드 또는 이를 코딩하는 폴리뉴클레오타이드를 포함하는 CRISPR 시스템, 상기 특이적 sgRNA 및 그의 이용에 관한 것이다. 본 발명에 따른 단일 가닥 가이드 RNA (sgRNA) 및 이를 이용한 CRISPR 시스템은 기존 sgRNA에 비하여 표적 DNA에 유의적으로 특이성 및 억제 효과를 향상시키는 바, 이러한 sgRNA와 이를 이용한 CRISPR 시스템은 유전자 가위를 이용한 유전자 교정용 조성물, 유전체 수준의 스크리닝, 암을 비롯한 다양한 질병의 치료제, 질병 진단 또는 이미징용 조성물 개발, 형질전환동물 개발 등의 폭넓은 분야에 이용될 수 있을 것으로 기대된다.
PCT/KR2018/015897 2017-12-14 2018-12-14 Crispr 시스템 기능 향상 방법 및 그의 이용 WO2019117660A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170172383 2017-12-14
KR10-2017-0172383 2017-12-14

Publications (2)

Publication Number Publication Date
WO2019117660A2 WO2019117660A2 (ko) 2019-06-20
WO2019117660A3 true WO2019117660A3 (ko) 2019-08-08

Family

ID=66819327

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/015897 WO2019117660A2 (ko) 2017-12-14 2018-12-14 Crispr 시스템 기능 향상 방법 및 그의 이용

Country Status (2)

Country Link
KR (1) KR102117016B1 (ko)
WO (1) WO2019117660A2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3096713A1 (en) 2018-04-19 2019-10-24 The Regents Of The University Of California Compositions and methods for gene editing
WO2021201653A1 (ko) * 2020-04-02 2021-10-07 중앙대학교 산학협력단 Crispr/cas9 시스템을 기반으로 한 유전체 편집 방법 및 이의 용도
KR102688555B1 (ko) * 2020-05-11 2024-07-25 중앙대학교 산학협력단 CRISPR/Cpf1 시스템을 기반으로 한 유전체 단일 염기 편집 방법 및 이의 용도
KR20220081949A (ko) * 2020-12-09 2022-06-16 재단법인 아산사회복지재단 온-타겟 활성이 유지되고 오프-타겟 활성이 감소된 가이드 rna 및 이의 용도
CN116949039A (zh) * 2022-04-15 2023-10-27 西湖实验室(生命科学和生物医学浙江省实验室) 基于crispr的成像标记系统及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016094867A1 (en) * 2014-12-12 2016-06-16 The Broad Institute Inc. Protected guide rnas (pgrnas)
WO2017106251A1 (en) * 2015-12-14 2017-06-22 President And Fellows Of Harvard College Cas discrimination using tuned guide rna
WO2017160752A1 (en) * 2016-03-14 2017-09-21 Intellia Therapeutics, Inc. Methods and compositions for gene editing
WO2017184786A1 (en) * 2016-04-19 2017-10-26 The Broad Institute Inc. Cpf1 complexes with reduced indel activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3230452A1 (en) * 2014-12-12 2017-10-18 The Broad Institute Inc. Dead guides for crispr transcription factors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016094867A1 (en) * 2014-12-12 2016-06-16 The Broad Institute Inc. Protected guide rnas (pgrnas)
WO2017106251A1 (en) * 2015-12-14 2017-06-22 President And Fellows Of Harvard College Cas discrimination using tuned guide rna
WO2017160752A1 (en) * 2016-03-14 2017-09-21 Intellia Therapeutics, Inc. Methods and compositions for gene editing
WO2017184786A1 (en) * 2016-04-19 2017-10-26 The Broad Institute Inc. Cpf1 complexes with reduced indel activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIYANG, Z. ET AL.: "The effect of sequence mismatches on binding affinity and endonuclease activity are decoupled throughout the Cas9 binding site", BIORXIV, August 2017 (2017-08-01), XP055629593, Retrieved from the Internet <URL:https://doi.org/10.1101/176255> *

Also Published As

Publication number Publication date
KR20190071621A (ko) 2019-06-24
WO2019117660A2 (ko) 2019-06-20
KR102117016B1 (ko) 2020-05-29

Similar Documents

Publication Publication Date Title
WO2019117660A3 (ko) Crispr 시스템 기능 향상 방법 및 그의 이용
JP2017522908A5 (ko)
WO2017027423A9 (en) Engineered crispr-cas9 compositions and methods of use
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
JP2019508051A5 (ko)
MX2021000810A (es) Sistemas y metodos para producir formulaciones de terapia genetica.
EA201792663A1 (ru) Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr
WO2017053431A3 (en) Allele selective gene editing and uses thereof
WO2016106401A3 (en) Rna agents for p21 gene modulation
EP4253551A3 (en) Novel crispr dna and rna targeting enzymes and systems
WO2016061286A3 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
WO2016115543A3 (en) Novel micro-dystrophins and related methods of use
WO2015126927A3 (en) Compositions for the inactivation of virus replication and methods of making and using the same
WO2016049024A3 (en) Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
WO2017049266A3 (en) Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing and compositions thereof
EP4372091A3 (en) Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
EA201791991A1 (ru) Способ улучшения способности противодействовать внедренным днк-содержащим вирусам растения
WO2020198509A3 (en) Modified oligonucleotides with increased stability
EP3533877A3 (de) Viraler vektor für den zielgerichteten gentransfer in gehirn und rückenmark
WO2010011283A3 (en) Fus/tls-based compounds and methods for diagnosis, treatment and prevention of amyotrophic lateral sclerosis and related motor neuron diseases
WO2017106202A3 (en) Gene therapy for ocular disorders
WO2021130537A3 (en) Compositions and methods for simultaneously modulating expression of genes
WO2017001570A3 (en) Atp-binding cassette family coding polyribonucleotides and formulations thereof
WO2017103094A3 (en) Means and methods for treating copper-related diseases
WO2020243702A3 (en) Rnai constructs for inhibiting scap expression and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18888851

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18888851

Country of ref document: EP

Kind code of ref document: A2